Pharming Group stock
Price history
−25.41% over the period1 year: from €1.45 (November 20, 2025) to €1.08 (November 20, 2026), −25.41%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | €1.08 |
| October 30, 2026 | €1.09 |
| September 30, 2026 | €0.89 |
| August 31, 2026 | €0.99 |
| July 31, 2026 | €0.88 |
| June 30, 2026 | €1.20 |
| May 29, 2026 | €1.15 |
| April 30, 2026 | €1.43 |
| March 31, 2026 | €1.43 |
| February 27, 2026 | €1.39 |
| January 30, 2026 | €1.71 |
| December 31, 2025 | €1.43 |
| November 28, 2025 | €1.44 |
| November 20, 2025 | €1.45 |
At a glance
The company
Develops and commercializes protein replacement therapies and precision medicines for rare diseases, including RUCONEST and Joenja
Latest results
Quarter to September 30, 2026 · EPS $0.03 (estimate $0.02)
TickerLandia's take on Pharming Group
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−40.51% from the 52-week high
Analysts · 4 analysts
Average target€2.24+107.56% vs. price
Buy 4 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: Pharming Group
Compared with similar companies: high risk, high earnings stability, and low price.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricelow34
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 38.0 53 EV/EBITDA 12.4 20 Price/book 3.01 25 Forward P/E 34.0 69 Price/sales 2.09 4 Profitabilityaverage49
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 87.7% 68 ROE 8.7% 43 ROA 6.4% 53 Operating margin 12.8% 40 Net margin 6.3% 42 Earnings stabilityhigh66
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 8.3% 78 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 53 Growthaverage60
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +22.30% 50 Revenue growth (year over year) +20.80% 49 Earnings growth (year over year) +74.90% 79 Financial strengthaverage45
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.75 70 Interest coverage 3.06 36 Debt/equitycounts in reverse: lower means more financial strength 0.39 28 Current ratio 3.23 45 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumaverage42
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +12.38% 82 Relative strength (6 months) −5.53% 43 1-year return −25.41% 8 Distance from 200-day average −5.99% 35 Riskhigh71
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 53.5% 96 Volatility (60 days) 40.3% 82 Beta (1 year) 0.59 36
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Pharming Group is pricier than similar companies
Pharming Group's P/E (trailing 12 months): 36.1, +145% against the median of a group of 7 similar companies (14.7).
Compared with 7 similar companies
| Metric | Pharming Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 36.1 | High | |
| Forward P/E | 32.2 | Middle | |
| Operating margin | 12.8% | Middle | |
| ROE | 8.7% | Middle | |
| Debt/equity | 0.39 | High |
Grey band: the middle half of the group; tick: the median; dot: Pharming Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$90.21M
Latest quarter · Q2 2026
Net income
$1.64M
Latest quarter · Q2 2026
Quarterly net margin
1.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- €765.47M
- P/E
- 36.1
- EPS
- €0.03
- Volume
- 8.02M
- Daily trading
- €12.81M
- Dividend yield
- 0.00%
How Pharming Group is changing
All resultsRevenue grew 12.1% a year on average over the last 5 years
Operating margin rose from 5.0% to 8.7%
Shares outstanding up 9.4% in 5 years
Returns
Pharming Group returns
€1,000 invested in Pharming Group 5 years ago, on November 22, 2021, would be worth €1,424 today: +42.38% in total, +7.33% per year. This is the price return only: dividends are excluded.
| Period | Pharming Group | AEX | €1,000 becomes |
|---|---|---|---|
| 1 month | +26.76% | −5.95% | €1,268 |
| 6 months | −2.57% | +3.14% | €974 |
| Year to date | −24.16% | +12.07% | €758 |
| 1 year | −25.41% | +14.04% | €746 |
| 3 years | +0.32% | +40.38% | €1,003 |
| 5 years | +42.38% | +30.76% | €1,424 |
| 10 years | +377.91% | +135.34% | €4,779 |
Over the last 6 months it has done better than 14% of the stocks in the Healthcare sector.
Price only, without dividends. Calculate your investment
The chart in detail
Pharming Group: technical analysis
Pharming Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 99.7% below its all-time closing high (€310.17, March 10, 2000).
- Trend
- No clear trend
- RSI (14 sessions)
- 52
- Between 30 and 70
- vs 200-session average
- −5.99%
Support and resistance
Price areas where Pharming Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance€1.37+27.12%2 touches, last on April 28, 2026
- Resistance€1.27+17.88%3 touches, last on July 9, 2026
- Resistance€1.20+11.21%2 touches, last on November 12, 2026
- Last price€1.08
- Support€1.07−0.67%2 touches, last on November 6, 2026
- Support€1.01−6.40%3 touches, last on August 28, 2026
- Support€0.98−9.75%2 touches, last on September 22, 2026
Volatility and risk
Over the last year it has moved less than the AEX.
- Beta (1 year) vs AEX
- 0.59
- Volatility (60 sessions, annualised)
- 40.3%
- Largest fall in the last year
- −53.51%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Pharming Group: seasonality
Average monthly price change over 28 years
Over the last 28 years, the strongest month for Pharming Group has been January: +11.94% on average, positive in 12 years out of 27. The weakest has been March: −8.83% on average, positive in 6 years out of 27. November, the current month, has been positive in 9 years out of 27 (+1.10% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +11.94% | −3.22% | 12 of 27 |
| February | +3.15% | −2.50% | 10 of 27 |
| March | −8.83% | −5.81% | 6 of 27 |
| April | +0.46% | −2.22% | 9 of 27 |
| May | −1.43% | −3.67% | 8 of 27 |
| June | +1.40% | −1.87% | 11 of 27 |
| July | −0.97% | +0.05% | 14 of 28 |
| August | +0.04% | +2.24% | 16 of 28 |
| September | −2.74% | −4.11% | 9 of 28 |
| October | +10.05% | −1.89% | 11 of 28 |
| November | +1.10% | −2.95% | 9 of 27 |
| December | +1.96% | −1.05% | 11 of 27 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Pharming Group and its competitors
Pharming Group N.V. develops and commercializes protein replacement therapies and precision medicines for rare diseases, with commercial activity in the United States, Europe and other markets worldwide. Its lead product is RUCONEST, a treatment for acute attacks of hereditary angioedema in adults and adolescents. Joenja, an oral medicine for activated phosphoinositide 3-kinase delta syndrome, is the other principal product, and the company continues to develop it alongside a partnership with Novartis.
- Headquarters
- Leiden, Netherlands
- Employees
- 407
- Founded
- 1988
- Chief executive
- Fabrice Chouraqui
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Pharming GroupPHARM | $841.25M | 12.8% | 36.1 | −2.57% |
| InventivaIVA | $890.8M | -5,980.9% | — | −33.75% |
| PhilogenPHIL | $905.96M | 79.1% | 3.67 | −5.63% |
| Basilea PharmaceuticaBSLN | $1.07B | 24.2% | 18.1 | +35.06% |
| GubraGUBRA | $730.02M | -73.1% | — | −22.24% |
| Pharma MarPHM | $1.1B | 21.3% | 14.7 | −41.56% |
Same industry or related industries, similar size. Compare Pharming Group with its competitors · Full profile
